Search research articles
Contact Us
Filters
Showing results (31-40 of 61) with videos related to
Page
of 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
Cancer
|
December 2, 2016
Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors
Ayse Selen Yilmaz, Hatice Gulcin Ozer, Jessica L Gillespie, et al.
Scientific Reports
|
November 15, 2017
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitration
Joseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 24, 2017
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Roberto Pili, David I Quinn, Hans J Hammers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2018
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
Bernard Escudier, Thomas Powles, Robert J Motzer, et al.
Scientific Reports
|
March 8, 2018
Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitration
Joseph Markowitz, Jiang Wang, Zach Vangundy, et al.
The Lancet. Oncology
|
August 21, 2019
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study
Moshe C Ornstein, Sumanta K Pal, Laura S Wood, et al.
Oncotargets and Therapy
|
October 13, 2016
MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches
Joseph Markowitz, Zachary Abrams, Naduparambil K Jacob, et al.
Journal for Immunotherapy of Cancer
|
November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
Brian I Rini, David F McDermott, Hans Hammers, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 61) with videos related to
Sort By:
Page
of 7
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
Cancer
|
December 2, 2016
Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors
Ayse Selen Yilmaz, Hatice Gulcin Ozer, Jessica L Gillespie, et al.
Scientific Reports
|
November 15, 2017
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitration
Joseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 24, 2017
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Roberto Pili, David I Quinn, Hans J Hammers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2018
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
Bernard Escudier, Thomas Powles, Robert J Motzer, et al.
Scientific Reports
|
March 8, 2018
Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitration
Joseph Markowitz, Jiang Wang, Zach Vangundy, et al.
The Lancet. Oncology
|
August 21, 2019
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study
Moshe C Ornstein, Sumanta K Pal, Laura S Wood, et al.
Oncotargets and Therapy
|
October 13, 2016
MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches
Joseph Markowitz, Zachary Abrams, Naduparambil K Jacob, et al.
Journal for Immunotherapy of Cancer
|
November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
Brian I Rini, David F McDermott, Hans Hammers, et al.
Page
of 7